Improved power for TB Phase IIa trials using a model-based pharmacokinetic–pharmacodynamic approach compared with commonly used analysis methods

Por Svensson, Robin J., Gillespie, Stephen H., Simonsson, Ulrika S. H.
Publicado no J Antimicrob Chemother (2017)

A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses

Por Svensson, Robin J., Aarnoutse, Rob E., Diacon, Andreas H., Dawson, Rodney, Gillespie, Stephen H., Boeree, Martin J., Simonsson, Ulrika S.H.
Publicado no Clin Pharmacol Ther (2017)

Forecasting Clinical Dose–Response From Preclinical Studies in Tuberculosis Research: Translational Predictions With Rifampicin

Por Wicha, Sebastian G., Clewe, Oskar, Svensson, Robin J., Gillespie, Stephen H., Hu, Yanmin, Coates, Anthony R.M., Simonsson, Ulrika S.H.
Publicado no Clin Pharmacol Ther (2018)

Improving treatment outcome assessment in a mouse tuberculosis model

Por Mourik, Bas C., Svensson, Robin J., de Knegt, Gerjo J., Bax, Hannelore I., Verbon, Annelies, Simonsson, Ulrika S. H., de Steenwinkel, Jurriaan E. M.
Publicado no Sci Rep (2018)

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis

Por Svensson, Elin M, Svensson, Robin J, te Brake, Lindsey H M, Boeree, Martin J, Heinrich, Norbert, Konsten, Sarah, Churchyard, Gavin, Dawson, Rodney, Diacon, Andreas H, Kibiki, Gibson S, Minja, Lilian T, Ntingiya, Nyanda E, Sanne, Ian, Gillespie, Stephen H, Hoelscher, Michael, Phillips, Patrick P J, Simonsson, Ulrika S H, Aarnoutse, Rob
Publicado no Clin Infect Dis (2018)